Birgitte Smith‐Sørensen

2.9k total citations · 2 hit papers
25 papers, 2.4k citations indexed

About

Birgitte Smith‐Sørensen is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Birgitte Smith‐Sørensen has authored 25 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Birgitte Smith‐Sørensen's work include Cancer-related Molecular Pathways (12 papers), Cancer Genomics and Diagnostics (7 papers) and Epigenetics and DNA Methylation (5 papers). Birgitte Smith‐Sørensen is often cited by papers focused on Cancer-related Molecular Pathways (12 papers), Cancer Genomics and Diagnostics (7 papers) and Epigenetics and DNA Methylation (5 papers). Birgitte Smith‐Sørensen collaborates with scholars based in Norway, United States and Switzerland. Birgitte Smith‐Sørensen's co-authors include Eivind Hovig, Anne‐Lise Børresen, Hilde Johnsen, Lars A. Akslen, Stephanie Geisler, Per Eystein Lønning, Jan Erik Varhaug, Turid Aas, Kevin P. Rice and C C Harris and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Birgitte Smith‐Sørensen

25 papers receiving 2.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Database of p53 gene somatic mutations in human tumors and cell lines.

1994 727 citations Eivind Hovig, Birgitte Smith‐Sørensen et al. PubMed profile →
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1996 608 citations Turid Aas, Anne‐Lise Børresen et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Birgitte Smith‐Sørensen Norway	17	1.4k	1.4k	674	299	289	25	2.4k
C Bucana United States	20	1.3k 0.9×	1.5k 1.1×	703 1.0×	368 1.2×	202 0.7×	37	2.9k
Stuart Lutzker United States	20	1.6k 1.1×	1.7k 1.3×	451 0.7×	204 0.7×	235 0.8×	30	3.4k
Steven J. Kuerbitz United States	10	1.6k 1.1×	1.8k 1.3×	473 0.7×	172 0.6×	206 0.7×	19	2.6k
Mark L. Levitt United States	16	1.1k 0.8×	799 0.6×	349 0.5×	464 1.6×	176 0.6×	43	1.9k
Sylvie Gazzéri France	36	1.6k 1.1×	2.5k 1.8×	677 1.0×	581 1.9×	157 0.5×	63	3.5k
Robert J.C. Slebos Netherlands	18	1.5k 1.0×	1.4k 1.0×	561 0.8×	903 3.0×	211 0.7×	24	2.7k
Audrey Petitjean France	9	1.3k 0.9×	1.3k 1.0×	704 1.0×	272 0.9×	195 0.7×	16	2.2k
Barry M. Kacinski United States	40	1.3k 0.9×	1.6k 1.2×	473 0.7×	218 0.7×	652 2.3×	94	4.1k
Tobias Grob Germany	25	954 0.7×	992 0.7×	396 0.6×	378 1.3×	201 0.7×	55	2.2k
Ying C. Henderson United States	25	1.0k 0.7×	1.3k 0.9×	509 0.8×	236 0.8×	337 1.2×	39	2.4k

Countries citing papers authored by Birgitte Smith‐Sørensen

Since Specialization

Citations

This map shows the geographic impact of Birgitte Smith‐Sørensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgitte Smith‐Sørensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgitte Smith‐Sørensen more than expected).

Fields of papers citing papers by Birgitte Smith‐Sørensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgitte Smith‐Sørensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgitte Smith‐Sørensen. The network helps show where Birgitte Smith‐Sørensen may publish in the future.

Co-authorship network of co-authors of Birgitte Smith‐Sørensen

This figure shows the co-authorship network connecting the top 25 collaborators of Birgitte Smith‐Sørensen. A scholar is included among the top collaborators of Birgitte Smith‐Sørensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgitte Smith‐Sørensen. Birgitte Smith‐Sørensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith‐Sørensen, Birgitte, Guro E. Lind, Rolf I. Skotheim, et al.. (2005). Frequent Promoter Hypermethylation of the O ⁶ - Methylguanine-DNA Methyltransferase (MGMT) Gene in Testicular Cancer. The Journal of Urology. 175(1). 154–155. 8 indexed citations

Andersen, Karin, Birgitte Smith‐Sørensen, Kjetil Boye, et al.. (2003). Interferon-γ suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. British Journal of Cancer. 88(12). 1995–2001. 17 indexed citations

Nygaard, Vigdis, Anders Løland, Marit Holden, et al.. (2003). Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics. 4(1). 11–11. 63 indexed citations

Smith‐Sørensen, Birgitte, Guro E. Lind, Rolf I. Skotheim, et al.. (2002). Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene. 21(57). 8878–8884. 61 indexed citations

Lothe, Ragnhild A., Birgitte Smith‐Sørensen, Merete Hektoen, et al.. (2001). Biallelic inactivation ofTP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes and Cancer. 30(2). 202–206. 39 indexed citations

Geisler, Stephanie, Birgitte Smith‐Sørensen, Daniel Betticher, et al.. (2000). p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy. Breast Cancer Research. 2(S1). 1 indexed citations

Smith‐Sørensen, Birgitte, et al.. (1998). Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. British Journal of Cancer. 78(3). 375–381. 39 indexed citations

Børresen‐Dale, Anne‐Lise, Eivind Hovig, & Birgitte Smith‐Sørensen. (1998). Detection of Mutations by Denaturing Gradient Gel Electrophoresis. Current Protocols in Human Genetics. 17(1). Unit 7.5–Unit 7.5. 4 indexed citations

Warren, William, Eivind Hovig, Birgitte Smith‐Sørensen, et al.. (1997). Detection of Mutations by Single‐Strand Conformation Polymorphism (SSCP) Analysis and SSCP‐Hybrid Methods. Current Protocols in Human Genetics. 15(1). Unit 7.4–Unit 7.4. 10 indexed citations

10.

Smith‐Sørensen, Birgitte & Eivind Hovig. (1996). CDKN2A (p16INK4A) somatic and germline mutations. Human Mutation. 7(4). 294–303. 77 indexed citations

11.

Aas, Turid, Anne‐Lise Børresen, Stephanie Geisler, et al.. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 2(7). 811–814. 608 indexed citations breakdown →

12.

Smith‐Sørensen, Birgitte & Eivind Hovig. (1996). CDKN2A (p16INK4A) somatic and germline mutations. Human Mutation. 7(4). 294–303. 6 indexed citations

13.

Krawczak, Michael, Birgitte Smith‐Sørensen, Jörg Schmidtke, et al.. (1995). Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Human Mutation. 5(1). 48–57. 48 indexed citations

14.

Smith‐Sørensen, Birgitte, Stephen Friend, Yu-Xin Yan, et al.. (1994). Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.. Journal of Clinical Oncology. 12(5). 925–930. 145 indexed citations

15.

Smith‐Sørensen, Birgitte, Mark C. Gebhardt, Peter Kloen, et al.. (1993). Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Human Mutation. 2(4). 274–285. 33 indexed citations

16.

Hovig, Eivind, Birgitte Smith‐Sørensen, Mark C. Gebhardt, et al.. (1992). No alterations in exon 21 of the RBI gene in sarcomas and carcinomas of the breast, colon, and lung. Genes Chromosomes and Cancer. 5(2). 97–103. 8 indexed citations

17.

Smith‐Sørensen, Birgitte, Eivind Hovig, Björn Andersson, & Anne‐Lise Børresen. (1992). Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE). Mutation research. Fundamental and molecular mechanisms of mutagenesis. 269(1). 41–53. 17 indexed citations

18.

Hovig, Eivind, Birgitte Smith‐Sørensen, Anton Brögger, & Anne‐Lise Børresen. (1991). Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutation Research Letters. 262(1). 63–71. 107 indexed citations

19.

Børresen, A L, Eivind Hovig, Birgitte Smith‐Sørensen, et al.. (1991). Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.. Proceedings of the National Academy of Sciences. 88(19). 8405–8409. 157 indexed citations

20.

Børresen, A L, Eivind Hovig, Birgitte Smith‐Sørensen, et al.. (1990). Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE).. PubMed. 340A. 389–98. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact